Search
[email protected]

DxTerity Diagnostics Announces the Launch of IFN-1 Test for Lupus

Jun 09, 2022

DxTerity Diagnostics today announced the commercial launch of their IFN-1 Test for patients with Systemic Lupus Erythematosus (SLE or lupus). The IFN-1 Test supports the advancement of precision medicine to improve the lives of patients living with lupus.

DxTerity’s test measures a key biomarker, Type-1 Interferon (IFN-1), an important indicator of SLE disease severity and prognosis. High IFN-1 levels have been shown to lead to higher likelihood of disease severity and an increased risk for the development of lupus nephritis in SLE patients. The DxTerity IFN-1 Test is the first commercial IFN-1 gene expression assay and is now available to order

Read the full article on PR Newswire.

 

Share this page on social

Ready to get started? See what Samba can do for you.